Home » USA Broker Ratings » Alkermes plc – Ordinary Shares – Consenus Indicates Potential 35.7% Upside
Company Interviews

Alkermes plc – Ordinary Shares – Consenus Indicates Potential 35.7% Upside

Alkermes plc – Ordinary Shares found using ticker (ALKS) have now 14 analysts covering the stock with the consensus suggesting a rating of ‘Hold’. The range between the high target price and low target price is between 63 and 26 with the average target price sitting at 44.07. With the stocks previous close at 32.48 this now indicates there is a potential upside of 35.7%. The day 50 moving average is 32.35 and the 200 moving average now moves to 39.62. The market capitalisation for the company is $5,052m. You can visit the company’s website by visiting: http://www.alkermes.com

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company’s marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes. It is also developing Aripiprazole Lauroxil NanoCrystal Dispersion; ALKS 5461 for the treatment of depressive disorder; ALKS 3831 to treat schizophrenia; BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; and ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; development and license agreement with AstraZeneca plc; and license and collaboration agreement with Biogen MA Inc. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.